Grafico Azioni Glaxosmithkline (LSE:GSK)
2 Mesi : Da Dic 2019 a Feb 2020
RNS Number : 1926Z
08 January 2020
Issued: 8 January 2020, London UK
Deborah Waterhouse, CEO of ViiV Healthcare, to join GSK Corporate Executive Team (CET)
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that Deborah Waterhouse, CEO of global specialist HIV company ViiV Healthcare, will join GSK's Corporate Executive Team (CET) with immediate effect. ViiV Healthcare is majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders.
Deborah joined GSK in 1996 and has worked in a number of commercial leadership roles in Europe, Asia-Pacific and the USA. She has a strong track record of performance in both specialty and primary care medicines and brings further commercial focus to the CET.
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com/about-us.
About ViiV Healthcare
ViiV Healthcare is a global specialist HIV company established in November 2009 by GlaxoSmithKline (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Shionogi joined in October 2012. The company's aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com.
UK Media enquiries: Simon Steel +44 (0) 20 8047 (London)
Mary Hinks-Edwards +44 (0) 20 8047 (London)
Analyst/Investor Sarah Elton-Farr +44 (0) 208 (London)
enquiries: 047 5194
Danielle Smith +44 (0) 20 8047 (London)
James Dodwell +44 (0) 20 8047 (London)
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Principal risks and uncertainties' in the company's Annual Report on Form 20-F for 2018.
Registered in England & Wales:
980 Great West Road
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact email@example.com or visit www.rns.com.
(END) Dow Jones Newswires
January 08, 2020 09:37 ET (14:37 GMT)